[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"self-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:self-injury":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,77,97,116,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100614574","pilot-trial-of-an-emotion-regulation-and-executive-functioning-intervention-for-self-injurious-thoughts-and-behaviors-sitbs-in-children-100614574",false,"NCT07281365","Pilot Trial of an Emotion Regulation and Executive Functioning Intervention for Self-Injurious Thoughts and Behaviors (SITBs) in Children","Proof-of-Concept Trial of an Emotion Regulation and Executive Functioning Intervention for SITBs in Children","Inclusion Criteria:\n\n* between the ages of 7-12\n* at least one caregiver\u002Flegal guardian able to participate (more permitted)\n* experienced at least one episode of SITBs within the last month\n* ability to attend weekly sessions in-person or via telehealth\n* ability to attend baseline and 12-week assessments in-person.\n* estimated verbal IQ of 70 or greater\n\nExclusion Criteria\n\n* symptoms interfering with ability to participate in assessments\u002Ftherapy (i.e., psychosis)\n* estimated verbal IQ\\\u003C70 or previous diagnosis of intellectual development disorder\n* requiring inpatient psychiatric stabilization or high-intensity intervention to prevent hospitalization\n* active substance use\n* ward of the state","ALL","7 Years","12 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to develop and test an outpatient intervention for preadolescents (ages 7-12) with self-injurious thoughts and behaviors (SITBs).\n\nThe main questions it aims to answer are:\n\n1. Does the newer intervention lead to better engagement of families in treatment compared to treatment as usual (TAU)?\n2. Is the new intervention feasible, acceptable, and appropriate?\n3. Does the new intervention lead to more improvements in SITBs, mental health symptoms, and treatment targets compared to TAU?\n\nPreadolescent participants with SITBs and their families will be randomized to either the new intervention or TAU, which will consist of the typical interventions the study therapist would use for preadolescents with SITBs. Participants will:\n\n1. Complete an initial baseline assessment to determine eligibility and assess SITBs, mental health symptoms, executive functioning, and emotion regulation\n2. Participate in a \\~weekly, outpatient intervention lasting around 3-4 months\n3. Complete additional assessments at mid-treatment, post-treatment, and 3-month follow-up\n4. Participate in an interview sharing their perceptions of the intervention",[27,28,29,30],"Self-injury","Suicidal Ideation and Behavior","Executive Functioning","Emotion Regulation",[32,33,34,35,36,37],"Preadolescents","Children","Self-Injury","Suicidal ideation and behavior","Randomized controlled trial","Feasibility","NOT_YET_RECRUITING","2026-05-13",{"date":41,"type":42},"2026-05-14","ACTUAL",{"date":44,"type":21},"2026-12",{"date":46,"type":21},"2028-05",{"name":48,"class":49},"University of Colorado, Denver","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100510577","manualized-assessment-and-treatment-model-of-challenging-behavior-100510577","NCT05928247","Manualized Assessment and Treatment Model of Challenging Behavior","Inclusion Criteria:\n\n1. children from ages 3 to 17;\n2. challenging behavior that occurs at least 10 times a day, despite previous treatment;\n3. challenging behavior maintained by social positive or automatic reinforcement;\n4. stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment;\n5. on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free;\n6. stable educational plan and placement with no anticipated changes during the child's treatment.\n\nExclusion Criteria:\n\n1. patients who do not meet the inclusion criteria;\n2. patients currently receiving 15 or more hours per week of treatment for their challenging behavior;\n3. DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism);\n4. a comorbid health condition or major mental disorder that would interfere with study participation;\n5. occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment (Betz, 2011);\n6. patients requiring changes to protective supports for self-injury or drug treatment, but the investigators will invite these patients to participate when protective supports and drug regimen are stable.",true,"3 Years","17 Years",{"count":60,"type":21},30,[24],"Despite decades of mounting single-case-design evidence for the efficacy of applied behavior analysis (ABA) and other approaches for the assessment and treatment of challenging behavior, an evidence-based comprehensive approach remains to exist. The current study will collect test the efficacy of a standardized manual for assessing and treating challenging behavior for individuals with severe and mild challenging behavior.",[64,65,34],"Problem Behavior","Aggression","RECRUITING","2026-05-04",{"date":69,"type":42},"2026-05-08",{"date":71,"type":21},"2026-12-31",{"date":73,"type":21},"2027-12-31",{"name":75,"class":49},"Rutgers, The State University of New Jersey",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":76},"100510335","basic-and-applied-research-on-extinction-bursts-100510335","NCT05925101","Basic and Applied Research on Extinction Bursts","Inclusion Criteria:\n\n1. children aged 3 to 17;\n2. problem behavior that occurs at least 10 times a day, despite previous treatment;\n3. problem behavior maintained by social positive reinforcement;\n4. stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment;\n5. on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free;\n6. stable educational plan and placement with no anticipated changes during the child's treatment.\n\nExclusion Criteria:\n\n1. patients currently receiving 15 or more hours per week of treatment for their problem behavior;\n2. DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism);\n3. a comorbid health condition or major mental disorder that would interfere with study participation;\n4. occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment;\n5. patients requiring changes to protective supports for self-injury or drug treatment, but we will invite these patients to participate when protective supports and drug regimen are stable.",{"count":84,"type":21},40,[24],"Although highly effective, treatments like FCT include extinction, which can have adverse side effects. The extinction burst, an increase in the frequency or intensity of destructive behavior at the start of treatment, is the most common side effect of extinction, and can increase the risk of harm to the patient and others. The goal of the current study is to evaluate the prevalence of extinction bursts when various parameters of reinforcement (i.e., rate, magnitude, quality) are manipulated.",[64,65,88],"Self Injury","2026-04-28",{"date":91,"type":42},"2026-04-29",{"date":93,"type":42},"2023-07-07",{"date":95,"type":21},"2028-05-31",{"name":75,"class":49},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":76},"100480563","extensions-of-resurgence-as-choice-100480563","NCT05537610","Extensions of Resurgence as Choice","Extensions of Resurgence as Choice: Basic and Clinical Studies","Inclusion Criteria:\n\n1. boys and girls from ages 3 to 17;\n2. problem behavior that occurs at least 10 times a day, despite previous treatment;\n3. problem behavior maintained by social positive reinforcement;\n4. stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment;\n5. on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free;\n6. stable educational plan and placement with no anticipated changes during the child's treatment.\n\nExclusion Criteria:\n\n1. patients who do not meet the inclusion criteria;\n2. patients currently receiving 15 or more hours per week of treatment for their problem behavior;\n3. DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism);\n4. a comorbid health condition or major mental disorder that would interfere with study participation;\n5. occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment;\n6. patients requiring changes to protective supports for self-injury or drug treatment, but we will invite these patients to participate when protective supports and drug regimen are stable.",{"count":60,"type":21},[24],"Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the child their way in the natural environment (e.g., caregiver is busy with an infant sibling). This form of treatment relapse is known as resurgence. The goal of the current study is to evaluate whether alternating sessions in which the child can have their way (i.e., \"on\" sessions) with sessions in which the child can not have their way (i.e., \"off\" sessions) helps to mitigate resurgence.",[64,65,34],"2026-04-14",{"date":110,"type":42},"2026-04-17",{"date":112,"type":42},"2023-02-01",{"date":114,"type":21},"2028-01-31",{"name":75,"class":49},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100599960","phase-2-propranolol-for-aggression-self-injury-and-severe-disruptive-behavior-in-adolescents-and-adults-with-autism-100599960","NCT07091279","Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism","Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism","Inclusion Criteria:\n\n* Age between 12-40 years.\n* Clinical best-estimate diagnosis of autism spectrum disorder\n* Occurrence of severe challenging behaviors, such as aggression, self-injury, and\u002For severely disruptive or destructive behavior, leading to safety concerns or serious impact of the quality of life, at least weekly over the past 2 months before screening.\n* Score in the ASD range on the Autism Diagnostic Observation Schedule conducted at the time of study entry or in the past 5 years\n* Clinical Global Impression Severity scale (CGI-S) score of 4 or above at Baseline\n* Aberrant Behavior Checklist-2 Irritability\u002FAgitation Subscale Score of 18 or above at Screening.\n* A resting pulse of greater than 60 and a resting blood pressure of greater than 100\u002F60.\n* Participant must have a designated study partner who spends a minimum of 5 hours\u002Fweek with the participant, and can, in the opinion of the investigator, provide a reliable report on the participant's behaviors, symptoms, and complete or supervise at-home safety monitoring and other assessments required during the study\n* Participants of childbearing potential who are sexually active must agree to practice effective contraception from time of screening through 30 days after their last dose of study drug. Effective contraception is the use of two methods of contraception: hormonal contraceptives or intrauterine device and barrier (i.e., condoms, diaphragm, or cervical cap).\n* Participant must be able to fully swallow study medication capsule.\n* English must be primary language for participant. Study partner must be able to consent in English and complete study related form in English.\n\nExclusion Criteria:\n\n* Those who are unable to provide informed consent and have no parent\u002Fguardian\u002Flegally authorized representative to provide informed consent for study enrollment\n* Change in psychotropic medication or behavioral intervention (except when caused by vocational, habilitation, or school schedule) within two months before randomization.\n* Asthma or history of any disorder involving bronchoconstriction in the past 5 years.\n* Cardiovascular history in which the use of propranolol at high doses would be contraindicated, as determined by consulting cardiologist (such as AV block, sick sinus syndrome, valvular pathologies, cardiomyopathies, or vascular disease).\n* Uncontrolled seizure disorder (a seizure within the past year and\u002For changes in seizure medication in the previous six months).\n* Diabetes mellitus\n* History of lactose intolerance that requires the potential participant to abstain from all dairy products or to take lactase supplements.\n* Medical history of renal or hepatic impairment.\n* Medical history of hypoglycemia\n* Inability to provide blood testing when there is a medical indication for blood testing to allow clinical safety determination by the study safety physician\n* Depressive episode currently or within the previous six months\n* History of allergy or adverse reaction to propranolol or another beta-blocker\n* Current use of any of the following: propafenone, quinidine, amiodarone, lidocaine, digitalis glycosides, calcium channel blockers, ACE inhibitors, clonidine, alpha blockers, reserpine, inotropic agents (epinephrine), isoproterenol and dobutamine, nonsteroidal anti-inflammatory drugs (indomethacin), antidepressants (MAO inhibitors, tricyclics), anesthetic agents (methoxyflurane, trichloroethylene), warfarin, neuroleptics (haloperidol), thyroxine, alcohol\n* Any other medical disorder or medication which would contraindicate the use of propranolol.\n* Is judged to be inappropriate for the study for any reason by the Investigator\n* Has recently participated in another investigational medication study or device study within last 3 months\n* Participant is unable to complete blood pressure or ECG safety assessments\n* If female, is pregnant or breastfeeding.","40 Years",{"count":125,"type":21},60,[127],"PHASE2","The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.",[130,131,65,132,27],"Autism Spectrum Disorder","Challenging Behaviour","Severe Disruptive Behaviour Disorders",[134,135,136,137,138,139,140,141,142,143,144],"autism","autism spectrum disorder","propranolol","severe disruptive behavior","aggression","challenging behavior","self-injury","randomized clinical trial","RCT","high dose propranolol","open label","2026-03-26",{"date":147,"type":42},"2026-03-30",{"date":149,"type":42},"2026-01-30",{"date":151,"type":21},"2028-12",{"name":153,"class":49},"Jeremy Veenstra-vanderweele",2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":175,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100547361","brief-admission-by-self-referral-for-individuals-with-self-harm-effects-on-compulsory-care-100547361","NCT06406972","Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care","Inclusion Criteria:\n\n* Living in the uptake area of Lund, Linköping, Helsingborg or Norrköping\n* Age 18-65 years at the time of inclusion\n* Admitted to hospital either diagnosed with ICD-10 diagnosis BPD F60.3, or admitted at least twice with Intentional self-harm X60-83 in combination with one of more of the following diagnoses ADHD (F90.0-F90.X), Bipolar disorder type 2, (F31.8W, F318A-F, F31.0, F31.8-9, F31.8W) or Autism, Atypical autism, Aspergers syndrome (F84.0, F84.1, F84.5) or Mild intellectual disability (F70.0-F70.9).\n\nExclusion Criteria:\n\n* not fulfilling inclusion criteria","18 Years","65 Years",{"count":164,"type":21},7000,"5 Years","OBSERVATIONAL","Brief Admission by self-referral (BA) is a standardized treatment model, providing patient-controlled and person-centered care. It was developed to reduce self-harm and compulsory care by promoting autonomy. Randomized clinical trials have not yielded significant between group differences with respect to inpatient care, including compulsory care. The major difficulty in evaluating BA is preventing the control group from cross-contamination, as in the implementation process of BA, all physicians, all inpatient and outpatient staff as well as managers need to be informed and undergo basic education regarding the intervention. As BA addresses a prevalent and frustrating issue in psychiatric health care, there is considerable risk that the approach leaks to the control group, reducing the possibility to detect between-group differences. In the current study this will be addressed through a register-based approach, comparing similar clinics, implementing BA at different timepoints over time. Individuals with traits of borderline personality disorder will be included and comparisons will be made with respect to compulsory care, voluntary inpatient care and mortality.",[27,169,170,171,172,173,174],"Suicide","Suicide, Attempted","Self-harm","Borderline Personality Disorder","Emergency Psychiatric","Hospitalizations Psychiatric",[176,177,178,179],"Brief Admission by self-referral","self-harm","traits of borderline personality disorder","compulsory care","2025-08-10",{"date":182,"type":42},"2025-08-14",{"date":184,"type":42},"2010-09-15",{"date":186,"type":21},"2025-12-31",{"name":188,"class":49},"Region Skane",4]